Alpha-GPC

Clinical trials in Alzheimer's and vascular dementia show meaningful cognitive benefit. In healthy adults the evidence is limited to small studies of power output and reaction time. An observational analysis has linked chronic use to increased stroke risk.

Alpha-GPC is what people buy when they have learned that most choline supplements do not reach the brain. Choline bitartrate, the cheap default, is poorly transported across the blood-brain barrier. Alpha-GPC crosses readily, which is why it dominates the serious end of the nootropic market alongside citicoline.

Its strongest evidence is clinical rather than recreational. In Alzheimer's disease and vascular dementia, trials at 1,200 mg daily have shown meaningful improvement on cognitive and functional scales — including a large multicentre Italian trial — and it is prescribed as a drug for exactly this purpose in several European countries. In conditions where cholinergic neurons are dying, supplying the precursor makes obvious sense, and it appears to work.

What that does not establish is benefit in a healthy twenty-eight-year-old whose cholinergic system is intact. The healthy-adult literature is thin: a handful of small studies report improved power output, faster reaction time, and increased growth hormone response to exercise, several of them conference abstracts rather than full papers. The physical-performance findings are arguably more consistent than the cognitive ones, which is not what most buyers expect.

The reason for caution is a genuine safety signal that most retailers do not mention. A secondary analysis of a large insurance database found that chronic alpha-GPC use was associated with a substantially increased ten-year risk of stroke. The proposed mechanism is that choline is converted by gut bacteria to TMAO, a metabolite independently linked to cardiovascular disease. This is observational, confounded by the fact that people prescribed alpha-GPC in that dataset had cognitive impairment and therefore higher baseline vascular risk, and it has not been confirmed in a trial. But it is not nothing, and it deserves to sit alongside the efficacy claims rather than beneath them.

Sensible use, then, is intermittent rather than daily: 300-600 mg before sessions where you want it, not a permanent fixture. If you have existing cardiovascular risk, the balance tips further toward caution, and citicoline — which carries no comparable signal — is a reasonable alternative.

How it works

Alpha-GPC crosses the blood-brain barrier efficiently and is cleaved to release choline, the direct precursor for acetylcholine — the neurotransmitter central to attention, learning, and neuromuscular signalling. It appears to raise brain choline more effectively than choline bitartrate or CDP-choline on a per-gram basis.